Medicilon Honors Revolution Medicines with Excellence in Client Partnership Award

In a notable ceremony held at Medicilon's Nanhui RD Center, Medicilon recognized Revolution Medicines with the prestigious "Excellence in Client Partnership Award." Dr. Yang Liu, Director of Medicinal Chemistry, alongside Senior Scientist Dr. Kristof Pota from Revolution Medicines, visited Medicilon’s facility, engaging in discussions that mapped out future collaborations and acknowledged the strides made in drug development.

A Celebration of Collaboration

The event commemorated the strong partnership formed over three years between Medicilon and Revolution Medicines. Dr. Maosheng Duan, President of Medicilon’s Drug Discovery and Pharmaceutical Research Divisions, highlighted the fruitful collaboration between the two organizations. This partnership is marked by a commitment to addressing RD technical challenges and a relentless focus on delivering high-quality therapeutic candidates.

During his address, Dr. Duan praised Revolution Medicines for its innovative approach in tackling complex targets such as KRAS—a target that was previously considered "undruggable." The FDA’s approval for their drug, Daraxonrasib, in August 2026 for metastatic pancreatic cancer represents not just a personal victory for the teams involved but also a beacon of hope for patients battling this aggressive form of cancer.

The Award Details

The Excellence in Client Partnership Award is a testament to the years of joint efforts and the mutual trust that has developed between both research and development teams. The recognition emphasizes the successful outcomes resulting from their collaboration, which exemplifies how combining expertise can lead to significant advancements in the pharmaceutical sector.

Forward-Looking Discussions

Beyond the award presentation, the discussions between Medicilon and Revolution Medicines delved into strategic priorities for the upcoming year. Dr. Jian Wang, Vice President of Medicilon, presented insights into the growth of the company, emphasizing the importance of their integrated RD platform that covers all aspects from target discovery to IND submissions. With accredited quality systems adhering to international standards, Medicilon’s focus on research excellence ensures a robust framework for ongoing and future projects.

Both parties also exchanged ideas on cross-regional data transfers and project management strategies, aiming to enhance the efficiency and success of RD collaborations that could transcend geographic barriers.

Laboratory Insights

The visit culminated in a guided tour of Medicilon’s state-of-the-art laboratories, where Drs. Liu and Pota witnessed first-hand the infrastructure supporting Medicilon’s R&D activities. The tour provided insights into the chemistry and oligonucleotide laboratories, as well as the API and preclinical research facilities, ensuring transparency and fostering a deeper understanding of Medicilon's rigorous quality management systems.

The strength of the Medicilon and Revolution Medicines collaboration is set to pave the way for more groundbreaking achievements in pharmaceutical development. As both companies look to the future, they remain committed to transforming scientific innovation into tangible solutions for patients in need.